A 26- Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India

The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.
The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).

开始日期2024-04-18

申办/合作机构

Eli Lilly & Co.

[+1]

NCT06717191

/ Completed临床4期IIT

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth With Diabetes in Pakistan

This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Pakistan

开始日期2022-06-09

申办/合作机构-

NCT06674135

/ Completed临床4期IIT

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh

开始日期2022-06-01

申办/合作机构

Bangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders

[+1]

100 项与甘精胰岛素生物类似药(Boehringer Ingelheim) 相关的临床结果

登录后查看更多信息

100 项与甘精胰岛素生物类似药(Boehringer Ingelheim) 相关的转化医学

登录后查看更多信息

100 项与甘精胰岛素生物类似药(Boehringer Ingelheim) 相关的专利（医药）

登录后查看更多信息

项与甘精胰岛素生物类似药(Boehringer Ingelheim) 相关的文献（医药）

2025-07-01·DIABETES OBESITY & METABOLISM

What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives

Review

作者: Chu, L. ; Abitbol, A.

Abstract:

Background:

The rising cost of insulins are significantly impacting health care expenditure, thereby limiting access to treatment for more people affected by diabetes. Fear and misunderstanding of insulin therapy have worsened with the emergence of biosimilar insulins. Biosimilars are not the same as generic medications. Generic medication contains identical ingredients to the reference, whereas biosimilar medication is highly comparable but not necessarily identical to the reference.

Results:

There are five biosimilar insulins currently available in Canada: insulin glargine (U‐100) as the biosimilar insulins, Basaglar® and Semglee®, insulin lispro (U‐100) as the biosimilar insulin, Admelog® and insulin aspart (U‐100) as the biosimilar insulins, Trurapi® and Kirsty ™. Recent clinical trials have demonstrated comparable efficacy, safety and immunogenicity for biosimilar insulins compared with reference insulins. The dosing of biosimilar insulins is also the same as the reference for initiating, switching (1:1) and titrating. Regulatory agencies, payors and clinical practice guideline committees are initiating biosimilar initiatives aimed at reducing costs, impacting more patients worldwide. While few studies have evaluated biosimilar insulin use in a real‐world clinical practice setting, the descriptive patterns retrieved from the LMC Diabetes Registry reflect the Ontario Ministry of Health's changes in biologic drug policy that were implemented to promote the use of biosimilar insulins.

Conclusion:

Many health care providers are largely unfamiliar with biosimilar insulins. This limits the acceptance of biosimilar insulins by patients, as it is related to the comfort of health care providers in educating patients. Tailoring effective conversations to patient needs ensures the best possible therapeutic outcomes.

Plain Language Summary:

This review article intends to review the efficacy and safety data from pivotal clinical trials with biosimilar insulins, as well as the regulatory and health economic considerations which underpin the safe and cost‐effective use of biosimilar insulin therapy. Biosimilars are not the same as generic medications. Generic medication contains identical ingredients to the reference, whereas biosimilar medication is highly comparable but not necessarily identical to the reference. There are five biosimilar insulins currently available in Canada: insulin glargine (U‐100) as the biosimilar insulins, Basaglar® and Semglee®, insulin lispro (U‐100) as the biosimilar insulin, Admelog® and insulin aspart (U‐100) as the biosimilar insulins, Trurapi® and Kirsty™. Data for biosimilars must be submitted in a stepwise approach to demonstrate similarity to the reference biologic under the following categories: structure & function, human clinical trials, comparative studies evaluating efficacy and safety and manufacturing quality control. Recent clinical trials have demonstrated comparable efficacy, safety and immunogenicity for biosimilar insulins compared with reference insulins. The dosing of biosimilar insulins is also the same as the reference for initiating, switching (1:1) and titrating. Health care providers are encouraged to stay up to date on the latest guidelines and recommendations regarding biosimilar insulin interchangeability to ensure safe and cost‐effective use of these products. Regulatory agencies, payors and clinical practice guideline committees are initiating biosimilar initiatives aimed at reducing costs, impacting more patients worldwide. While few studies have evaluated biosimilar insulin use in a real‐world clinical practice setting, the descriptive patterns retrieved from the LMC Diabetes Registry reflect the Ontario Ministry of Health's changes in biologic drug policy that were implemented to promote the use of biosimilar insulins. A summary of adults with diabetes from this registry showed 3.8% of individuals with T1D were prescribed Basaglar® before April 2023 compared to 12.0% after January 2024. For the T2D cohort, the use of basal biosimilar insulins, Basaglar® and Semglee®, similarly increased by approximately 10% and 2% after January 2024, respectively. The use of bolus biosimilar insulins also increased after January 2024 by approximately 28% in the T1D cohort and 60% in the T2D cohort using insulin therapy. Many health care providers are largely unfamiliar with biosimilar insulins. This limits the acceptance of biosimilar insulins by patients, as it is related to the comfort of health care providers in educating patients. People living with diabetes must have access to safe and effective treatment options, and they should be able to obtain appropriate medications at an affordable price and in a fair and timely manner.

2025-02-01·The Journal of the Association of Physicians of India

Safety and Efficacy of Biosimilar Insulin Glargine (Basaglar) in Indian Patients with Type 2 Diabetes Mellitus: Results from a Multicenter, Open-Label, Single-Arm, Phase 4 Trial (ABEX)

Article

作者: Arora, Rohit ; Bhattacharya, Indranil ; Shah, Parag ; Shamanna, Paramesh ; Spaepen, Erik ; Brahme, Keyur ; Saboo, Banshi ; Desai, Piyush ; Khandelwal, Deepak

BACKGROUND:

Basaglar^®, a biosimilar of glargine, was approved in India for the treatment of diabetes in patients aged >2 years. The efficacy and safety of biosimilar insulin glargine (Basaglar) have been previously established in Phase 3 clinical trials, ELEMENT-1, -2, and -5. This study assessed the safety and efficacy of Basaglar in Indian patients with type 2 diabetes mellitus (T2DM).

MATERIALS AND METHODS:

This multicenter, open-label, single-arm, phase 4 trial included Indian patients with insulin-naïve T2DM with glycated hemoglobin A1c (HbA1c) ≥7.0 to <11.0% who were receiving ≥2 oral antihyperglycemic drugs and/or a glucagon-like peptide-1-receptor agonist. Patients received Basaglar once daily for 24 weeks, excluding 4 weeks of safety follow-up. The primary endpoint was the incidence of total hypoglycemic events [blood glucose (BG) ≤54 mg/dL (≤3.0 mmol/L)] at week 24.

RESULTS:

Of the 259 patients enrolled, 64.1% were males, had mean [standard deviation (SD)] age 52.1 (11.38) years, and had diabetes for mean (SD) 6.75 (5.16) years. The mean HbA1c (SD) levels significantly improved from baseline to week 24 [-1.03 (1.554); p <0.0001] and Basaglar titration doubled from baseline. Total hypoglycemic events were reported in 10 (3.86%), 7 (2.70%), and 4 (1.54%) patients during weeks 0-24, 0-12, and 12-24, respectively. Ten patients (3.90%) reported 12 adverse events (AE; 11 mild and moderate, one severe). One death, unrelated to Basaglar, was reported.

CONCLUSION:

Basaglar was well tolerated with few hypoglycemic events and significantly reduced HbA1c and BG from baseline in Indian insulin-naïve patients with T2DM.

2025-01-01·BMJ Open

Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries

Article

作者: Morolla, Davide ; von Schoen-Angerer, Tido ; Ewen, Margaret ; Beran, David ; Raviglione, Mario

Objective:

Quantify insulin glargine prices following the market introduction of biosimilars. Examine price levels and price changes for originator and biosimilars, by country.

Methods:

Retrospective quantitative analysis using insulin glargine pricing data, both of the originator product and its biosimilars. Segmented regression analysis using a dual-model approach: pooled and country-specific.

Setting:

28 European countries using data from the European Medicine Price Database for the period 2013–2023.

Main outcome measures:

Price variations between countries were analysed to assess trends and correlations before and after biosimilar market entry.

Results:

In the 28 countries studied, cost of insulin glargine underwent a median 21.6% decrease overall in the last decade (p<0.001). In 2022, the median price was €9.0 for the originator (first to market) Lantus (IQR €8.1–€10.4), €8.9 for the biosimilar Abasaglar (IQR €7.6–€10.1) and €7.0 for the biosimilar Semglee (median €7.0; IQR €6.8–€7.5). The originator price was higher than biosimilars (p=0.009). Biosimilar market entry was associated with an overall significant price reduction of the originator, both immediately after entry (p<0.001) and in the long-term postentry (p<0.001). No significant correlation was observed between the price of insulin and the countries’ economic indicators.

Conclusion:

This is the first study to show the price trend of insulin glargine and its correlation with the introduction of biosimilars, in Europe. A significant price reduction of the originator was observed after biosimilars entered the market. The median cost of biosimilars was lower than the originator, although with substantial differences between individual countries and producers.

231

项与甘精胰岛素生物类似药(Boehringer Ingelheim) 相关的新闻（医药）

2025-10-16

·EndPoints

California to offer its own, cheaper version of insulin pens

California Gov. Gavin Newsom on Thursday unveiled a deal to keep insulin glargine pen prices down for diabetics in the state, offering Biocon’s interchangeable biosimilar for a suggested retail price of about half of what pharmacies currently pay for competitors offered by Eli Lilly and Sanofi. Beginning Jan. 1, 2026, the cheaper insulin for Californians, offered under the CalRx brand, will cost no more than $55 per five-pack of pens, Newsom said. The price was forged via a deal between Virginia-based nonprofit generic drugmaker Civica Rx and India-based Biocon Biologics. Biocon and Civica on Thursday announced a “multiyear” private label agreement where Biocon will manufacture and supply insulin glargine to Civica, and Civica will commercialize it under Biocon Biologics’ existing marketing approval. The push from California shows how states may look to take unique approaches to bring down drug prices, particularly for biologics like insulin, where prices remain persistently high despite ongoing competition. Civica expects to launch the same price for its insulin glargine pens in all 50 states on Jan. 1, the company’s chief government affairs officer Allan Coukell told Endpoints News . Biocon said it will continue to directly commercialize its own interchangeable biosimilar insulin glargine, known as Semglee, which launched in the US in November 2021. The current list price of Semglee is almost 10 times higher than what the CalRx biosimilar will retail at for a pack of five pens. In March 2022, Civica laid out plans for its suggested retail price of no more than $55 per pack of five pens, which compared at the time with a list price of $425 for Sanofi’s Lantus, $404 for Semglee, and $148 for unbranded Semglee. Now, Lilly’s insulin glargine, known as Rezvoglar, retails at about $89 per pack, according to the governor’s office, while its Basaglar pens cost more than $310. Lantus retails at $92, while Sanofi’s Toujeo version sells for $411 for a pack of five. “California didn’t wait for the pharmaceutical industry to do the right thing — we took matters into our own hands. By beginning the process to manufacture our own insulin and pricing it at a maximum cost of $11 a pen in a five-pack, California and Civica are showing the nation what it looks like to put people over profits,” Newsom said in a statement . Newsom also signed a bill on Monday that would ensure consumer cost-sharing for insulin at $35 for a month-long supply.

引进/卖出上市批准

2025-10-16

·药时代

头对头达格列净！礼来orforglipron两项三期研究报阳

药时代寻找对创新药Biotech 实实在在感兴趣且资金充沛的投资公司请立即联系药时代BD团队（BD@drugtimes.cn）！正文共：2600字预计阅读时间：7分钟今年8月，礼来公布第二季度业绩，核心产品Tirzepatide大卖147.34亿美元，有望冲击今年药王宝座，并同时上调了全年指引。然而，业绩向好，股价却暴跌。礼来当日股价跌去14%，市值蒸发约1000亿美元。造成这一剧烈波动的主要原因是，其在研口服GLP-1小分子orforglipron的三期临床ATTAIN-1数据变脸，在非头对头情况下，其减重数据不及司美格鲁肽，即36mg高剂量组治疗72周减重11.5%，而司美格鲁肽2.4mg剂量组治疗72周减重幅度为15.1%。也就是说，仅凭orforglipron一款药物的一项研究结果，就给礼来造成了千亿美元市值的损失。资本市场用真金白银印证了对该药的重视，或者说对口服GLP-1小分子赛道的看好。 2025年10月15日，礼来宣布旗下口服GLP-1小分子orforglipron在两项三期研究中获得积极结果。受此消息影响，礼来股价小幅上扬1.75%，市场即将重回8000亿美元大关。头对头达格列净此次公布的这两项研究，分别为与甘精胰岛素联用的ACHIEVE-5研究，以及头对头达格列净的ACHIEVE-2研究。两项研究均针对二型糖尿病患者。 ACHIEVE-5研究一项为期40周的III期随机、双盲、安慰剂对照研究，旨在接受甘精胰岛素（联用或不联2二甲双胍/SGLT-2抑制剂）治疗仍血糖控制不佳的2型糖尿病患者中评估orforglipron（3mg/12mg/36mg）的疗效与安全性。结果显示，546名受试者在接受治疗40周后，相较与安慰剂组，orforglipron联用甘精胰岛素可显著降低糖化血红蛋白（A1C）。图片来源：礼来官网 ACHIEVE-2研究则是一项为期40周的III期随机、活性对照、开放标签研究，旨在二甲双胍控制不佳的2型糖尿病患者中，比较orforglipron（3mg/12mg/36mg）与达格列净10mg的疗效与安全性。达格列净最早于2012年获EMA批准上市，是全球首个上市的SGLT-2抑制剂，于2017年进入我国。根据公开资料显示，2024年全国医院终端市场该药销售额达65亿元，稳坐国内口服降糖药“销冠”之位。结果显示，962名受试者在接受治疗40周后，所有剂量组在主要终点上均优于达格列净。图片来源：礼来官网安全性方面，两项研究中orforglipron的总体安全性、耐受性以及治疗中断率与之前的研究一致。最常见不良事件与胃肠道相关，严重程度通常为轻度至中度。未观察到肝脏安全信号。值得一提的是，ACHIEVE-2研究是礼来开展的第二项头对头研究。第一项是头对头口服司美格鲁肽的ACHIEVE-3研究。结果显示，在1698名经二甲双胍治疗血糖控制不佳的2型糖尿病成人中，治疗52周时，orforglipron所有剂量组均达到了主要终点和所有关键次要终点，在A1C和体重改善方面均优于口服司美格鲁肽。图片来源：礼来官网对此，礼来心血管代谢产品开发高级副总裁Jeff Emmick博士表示："Orforglipron在2型糖尿病临床试验中已连续证明其优于两种活性对照药物的疗效。这些突破性数据共同奠定了orforglipron成为2型糖尿病治疗新标准的潜力。" 信达生物高级副总裁钱镭博士也曾在采访中表示：“实际上，礼来正在开展一项研究，使用替尔泊肽把体重降下来之后，再以口服小分子药物长期续贯治疗，这也是一个非常合理的思路。” GLP-1的下一站：口服化目前，关于GLP-1赛道已经站满了人。随着诺和诺德新任CEO掌舵，并于前几日砍掉了公司细胞疗法部门，其与礼来就GLP-1的竞争将势必加剧。推荐阅读：又一MNC终止细胞治疗研发不仅如此，作为最早布局口服GLP-1小分子的辉瑞，在多款口服GLP-1药物因肝毒性或胃肠道副作用等问题先后终止研发，甚至一度全面退出了该赛道后，于今年9月22日，以72亿美元收购了Metsera，携GLP-1月制剂MET-097i重返赛场。未来，GLP-1新的增长点已经明确，减重增肌、超长效制剂以及口服制剂。其中，口服制剂只算是一只脚已经迈入，这只脚就是诺和诺德的口服版司美格鲁肽，其通过SNAC技术成功实现了对GLP-1多肽分子的递送。但该药也存在明显短板：严格要求空腹、生物合成复杂产能有限、成本高、运输条件苛刻等。且由于诺和诺德的专利壁垒，口服小分子成为了一条“另起炉灶”的聪明策略。目前，这条路上除了Orforglipron，还有Viking的VK2735、罗氏收购的CT-996，以及Rhythm的bivamelagon等多款重磅产品，正奋起直追。面对追赶，诺和诺德推出GLP-1/胰淀素受体激动剂Amycretin；礼来加速推进Orforglipron的上市，并不断拓展新适应症，包括但不限于膝关节骨关节炎疼痛、阻塞性睡眠呼吸暂停（OSA）以及压力性尿失禁等。这就是GLP-1的魅力，不仅在减重和降糖方面展现出的革命性疗效，还能还来心血管获益、肾脏获益等额外优势。可以说，玩家虽多，但架不住赛道大，且这一赛道仍在不断扩大。国内方面，口服GLP-1小分子同样竞争激烈。2023年11月，诚益生物的口服小分子GLP-1受体激动剂ECC5004，以高达20.1亿美元的潜在交易总额授权给了阿斯利康。该产品是基于Orforglipron的分子结构优化而来，显著提升了口服生物利用度，拟用于治疗肥胖症、2型糖尿病及相关合并症。今年10月8日，诚益生物港股IPO申请获得受理，有望成为小分子GLP-1第一股。此外，今年来还有恒瑞、翰森、先为达、石药等药企相继有口服GLP-1小分子出海。一个个造富神话的诞生，更是牵动着更多投资人与制药人的热情。根据辉瑞发布的《Near-Term Launches High-Value Pipeline Day》预测，2030年GLP-1市场的规模将达到约900亿美元，口服GLP-1RA预计到2030年将占据GLP-1市场约30%的份额。其主要原因是患者对口服制剂的偏好较高。目前，药时代BD团队正在为一款具有同类最佳减重与食欲抑制作用的口服小分子GLP-1受体激动剂项目寻找潜在合作伙伴。项目简介项目代号：DT-20250717-078 项目名称：一款用于治疗2型糖尿病、肥胖的口服小分子GLP-1受体激动剂适应症：2型糖尿病（T2D）、肥胖药物类型：小分子靶点：GLP-1 产品阶段：PCC阶段项目亮点： 1. 具有卓越的口服药代动力学特性; 2. 具有同类最佳的减重与食欲抑制作用; 3. 在超低剂量下具有高效降糖作用; 4. 安全性良好，具有宽泛的安全治疗窗口; 5. 低CYP450抑制风险、低肝毒性风险、无遗传毒性。合作需求：license-out(global或 ex-China right) 如果贵公司对该项目感兴趣，欢迎立即联系药时代BD团队！

临床3期上市批准临床2期财报临床失败

2025-10-16

·医药观澜

礼来小分子GLP-1受体激动剂在两项3期临床中显示优效控糖效果

10月15日，礼来公司（Eli Lilly and Company）公布了ACHIEVE-2与ACHIEVE-5两项3期临床试验的积极顶线结果。ACHIEVE-2是该研究系列的第二项头对头对照研究，评估了orforglipron对比一款SGLT-2抑制剂在经二甲双胍治疗血糖控制不佳的2型糖尿病成人中的疗效。ACHIEVE-5则评估了orforglipron对比安慰剂在经滴定甘精胰岛素治疗（联用或不联用二甲双胍和/或SGLT-2抑制剂）血糖控制不佳的2型糖尿病成人中的疗效。两项研究在第40周时，在有效性估计目标和治疗方案估计目标下，orforglipron（3mg、12mg、36mg）均达成主要及所有关键次要终点，实现糖化血红蛋白（A1C）显著降低，并减轻体重及改善多项心血管风险因子，研究结果均与此前公布的2型糖尿病相关研究一致。 Orforglipron是一种在研的、每日一次口服的小分子（非肽类）GLP-1受体激动剂（GLP-1 RA）。该药物可在全天任何时间服用，对饮食和饮水不加以限制。目前，礼来正在进行该产品用于治疗2型糖尿病，以及用于肥胖或至少伴有一种体重相关合并症的超重成人进行体重管理的系列3期研究。此外，礼来还在研究该产品作为治疗肥胖成人的阻塞性睡眠呼吸暂停、高血压及骨关节炎疼痛的潜在可能。 ACHIEVE-2和ACHIEVE-5研究结果显示：在ACHIEVE-2研究中，orforglipron实现糖化血红蛋白（A1C）降低1.7%，对照药降低0.8%，达到主要研究终点；在ACHIEVE-5研究中，orforglipron与甘精胰岛素联用，A1C进一步降低了2.1%，达到主要研究终点。在两项研究中，orforglipron的整体安全性、耐受性及治疗中断率均与既往研究一致。最常见的不良事件为胃肠道相关反应，通常为轻度至中度。未观察到肝脏安全性信号。上述研究的详细结果将于此后的医学会议上公布，并发表在同行评审期刊上。ACHIEVE研究系列的最后一项全球注册研究ACHIEVE-4的研究结果预计将于2026年第一季度公布。礼来计划于2026年向全球监管机构递交orforglipron用于2型糖尿病的上市申请，用于治疗肥胖的申请预计将于今年年底前递交。参考资料： [1] 礼来口服GLP-1RA orforglipron在两项成功3期临床研究中显示出优效的控糖效果.From https://mp.weixin.qq.com/s/efjdaL7bcCbDJkoiEbz7BQ 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床结果临床3期临床2期

100 项与甘精胰岛素生物类似药(Boehringer Ingelheim) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03250	甘精胰岛素生物类似药(Boehringer Ingelheim)	A10AE04	DB00047

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
1型糖尿病	美国	Eli Lilly & Co.	2015-12-16
2型糖尿病	美国	Eli Lilly & Co.	2015-12-16
糖尿病	欧盟	Eli Lilly Nederland BV	2014-09-09
糖尿病	冰岛	Eli Lilly Nederland BV	2014-09-09
糖尿病	列支敦士登	Eli Lilly Nederland BV	2014-09-09
糖尿病	挪威	Eli Lilly Nederland BV	2014-09-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04153981 (CTgov)	临床4期	2型糖尿病	304	Insulin Glargine	積觸膚膚糧衊餘糧選鬱 = 獵廠製繭鹹願築餘廠窪顧觸夢築選願遞夢醖廠 (鹽膚憲鏇簾鹽醖鑰觸築, 獵繭齋艱衊壓選夢鏇憲 ~ 蓋夢襯簾獵願製繭艱鹽) 更多	-	2024-02-15
NCT03338023 (Pubmed) 人工标引	临床3期	1型糖尿病	272	insulin lispro+LY2963016	膚築積醖獵淵鬱構鑰構(鏇衊齋築網顧獵網襯淵) = 選蓋衊製範壓範糧衊糧夢蓋鑰鏇製淵選餘廠觸 (鏇蓋餘夢積獵艱衊願廠, 0.07)	相似	2021-10-01
				insulin lispro+insulin glargine	膚築積醖獵淵鬱構鑰構(鏇衊齋築網顧獵網襯淵) = 構築襯製範淵襯願構繭夢蓋鑰鏇製淵選餘廠觸 (鏇蓋餘夢積獵艱衊願廠, 0.07)
NCT03338010 (Pubmed \| Diabetes Obes Metab) 人工标引	临床3期	2型糖尿病	536	LY2963016	壓鑰觸廠獵蓋齋鹽艱獵(觸鏇積蓋窪鏇網窪繭鬱) = 鹹艱餘獵積選築鏇壓鏇遞觸淵齋願壓築遞繭襯 (願衊淵鹹醖窪醖餘繭鑰 )	非劣	2021-08-01
				insulin glargine	壓鑰觸廠獵蓋齋鹽艱獵(觸鏇積蓋窪鏇網窪繭鬱) = 鏇齋艱齋繭網觸選糧鹹遞觸淵齋願壓築遞繭襯 (願衊淵鹹醖窪醖餘繭鑰 )
NCT03338010 (CTgov)	临床3期	2型糖尿病	536	LY2963016 (LY2963016)	餘壓鬱餘簾襯膚壓膚網(鹹膚膚糧網構淵網顧鹽) = 淵選鏇繭艱窪鹽選餘艱鹹醖糧鏇膚壓壓鹽衊衊 (繭鹽壓鹽襯願鬱鬱網壓, 0.043) 更多	-	2021-05-25
				Lantus® (Lantus®)	餘壓鬱餘簾襯膚壓膚網(鹹膚膚糧網構淵網顧鹽) = 簾餘顧積鹽窪網夢構膚鹹醖糧鏇膚壓壓鹽衊衊 (繭鹽壓鹽襯願鬱鬱網壓, 0.062) 更多
NCT03338023 (ABES, CTgov)	临床3期	1型糖尿病	272	LY2963016+Insulin Lispro (LY2963016 + Insulin Lispro)	鏇築構膚製獵襯淵餘淵(獵窪衊糧襯壓製積淵壓) = 鑰觸遞鬱繭糧壓築繭鹽憲簾壓選壓繭齋廠網製 (築獵獵範築積選繭積構, 0.071) 更多	-	2021-03-29
				Lantus®+Insulin Lispro (Lantus® + Insulin Lispro)	鏇築構膚製獵襯淵餘淵(獵窪衊糧襯壓製積淵壓) = 餘鹽糧獵廠製選觸獵鏇憲簾壓選壓繭齋廠網製 (築獵獵範築積選繭積構, 0.071) 更多
NCT03555305 (CTgov)	临床1期	-	58	Insulin Glargine (0.5 U/kg Insulin Glargine)	廠醖築糧衊齋艱窪製艱(簾鑰艱淵鹹糧製淵遞淵) = 夢壓憲積繭遞齋鑰鹹壓醖鏇獵網憲構艱製鬱願 (憲選糧醖餘選築衊獵餘, 31) 更多	-	2020-11-24
				Lantus (0.5 U/kg Lantus)	廠醖築糧衊齋艱窪製艱(簾鑰艱淵鹹糧製淵遞淵) = 築壓糧壓繭夢夢選鬱憲醖鏇獵網憲構艱製鬱願 (憲選糧醖餘選築衊獵餘, 33) 更多
NCT02302716 (ELEMENT 5, Pubmed \| Clin Drug Investig)	临床3期	2型糖尿病	493	Lilly insulin glargine (LY IGlar)	願繭糧鑰鑰窪憲壓廠選(顧壓廠願積鹽構餘齋範) = 糧選窪蓋窪簾齋憲網鹽餘齋願鬱蓋選網鏇範願 (齋顧鹽鏇衊遞夢醖鏇醖 )	积极	2019-08-01
				Insulin glargine (IGlar)	願繭糧鑰鑰窪憲壓廠選(顧壓廠願積鹽構餘齋範) = 憲鏇築範鏇獵鑰膚艱顧餘齋願鬱蓋選網鏇範願 (齋顧鹽鏇衊遞夢醖鏇醖 )
NCT02302716 (ELEMENT 5, Pubmed) 人工标引	临床3期	2型糖尿病	493	Insulin Glargine	夢簾積廠積廠衊鬱鏇選(艱顧顧顧顧積廠積膚網) = 廠齋繭網廠鬱窪簾顧鬱築壓鏇鹹壓廠簾鹹鬱壓 (憲齋餘築觸製鹹積構衊 )	相似	2019-02-01
				Lantus	夢簾積廠積廠衊鬱鏇選(艱顧顧顧顧積廠積膚網) = 願齋糧鏇顧範醖鹹構獵築壓鏇鹹壓廠簾鹹鬱壓 (憲齋餘築觸製鹹積構衊 )
NCT02302716 (ELEMENT 5, CTgov)	临床3期	2型糖尿病	493	LY2963016+Oral Antihyperglycemic Medication (LY2963016)	鹹憲鑰鹹鏇觸夢遞簾壓(衊鹹壓餘淵願鏇築製齋) = 廠衊鑰範選鹽憲觸糧鹽願構齋艱選齋鹹夢淵齋 (顧醖蓋膚獵襯餘鏇願選, 0.066) 更多	-	2017-10-24
				Oral Antihyperglycemic Medication+LANTUS® (LANTUS®)	鹹憲鑰鹹鏇觸夢遞簾壓(衊鹹壓餘淵願鏇築製齋) = 獵鏇膚鹹壓醖憲憲窪構願構齋艱選齋鹹夢淵齋 (顧醖蓋膚獵襯餘鏇願選, 0.067) 更多
NCT01421459 (ELEMENT 2, Pubmed \| Diabetes Obes Metab) 人工标引	临床3期	2型糖尿病	756	LY2963016	糧獵顧網選鏇繭衊窪蓋(衊遞簾簾願鬱顧網艱窪) = 範獵積鑰願繭廠壓鬱衊淵簾蓋簾醖願願顧夢繭 (憲鹽壓鹹襯觸獵築獵願 )	积极	2015-08-01
				insulin glargine	糧獵顧網選鏇繭衊窪蓋(衊遞簾簾願鬱顧網艱窪) = 鹽範淵憲鏇簾憲醖鑰膚淵簾蓋簾醖願願顧夢繭 (憲鹽壓鹹襯觸獵築獵願 )